Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Small Cell Lung Cancer”

160 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 160 results

Early research (Phase 1)Ended earlyNCT05573035
What this trial is testing

Investigate LYL845 in Adults With Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerColorectal Cancer
Lyell Immunopharma, Inc. 39
Testing effectiveness (Phase 2)Study completedNCT00951613
What this trial is testing

NK012 in Patients With Relapsed Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Nippon Kayaku Co., Ltd. 72
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07206563
What this trial is testing

Penfluridol for Relapsed/Refractory Small Cell Cancers

Who this might be right for
Small Cell CarcinomaSmall Cell Carcinoma of LungSmall Cell Lung Cancer ( SCLC )+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 33
Early research (Phase 1)Study completedNCT03639194
What this trial is testing

ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
AbbVie 132
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Testing effectiveness (Phase 2)Study completedNCT00003281
What this trial is testing

Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 84
Testing effectiveness (Phase 2)Study completedNCT00431015
What this trial is testing

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer
Infinity Pharmaceuticals, Inc. 88
Early research (Phase 1)Looking for participantsNCT06484816
What this trial is testing

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Non Small Cell Lung CancerAdvanced Solid TumorHematologic Malignancy
Shenzhen TargetRx Co., Ltd. 90
Early research (Phase 1)Looking for participantsNCT06348797
What this trial is testing

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

Who this might be right for
Small Cell Lung Cancer Extensive Stage
Sichuan University 30
Testing effectiveness (Phase 2)Study completedNCT00085813
What this trial is testing

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
GlaxoSmithKline 70
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Very early researchUnknownNCT03060343
What this trial is testing

Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Yu Fenglei 10
Early research (Phase 1)Study completedNCT01931787
What this trial is testing

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Who this might be right for
Recurrent Small Cell Lung Cancer
Wake Forest University Health Sciences 15
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Ended earlyNCT02769962
What this trial is testing

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Who this might be right for
Urothelial CarcinomaUrothelial CancerLung Neoplasms+2 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Ended earlyNCT04210037
What this trial is testing

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Ascentage Pharma Group Inc. 28
Testing effectiveness (Phase 2)Study completedNCT00405951
What this trial is testing

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Gemin X 47
Testing effectiveness (Phase 2)Study completedNCT00010218
What this trial is testing

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 55
Testing effectiveness (Phase 2)Study completedNCT01852578
What this trial is testing

Cabazitaxel in Relapsed and Metastatic NSCLC

Who this might be right for
NSCLC
Hellenic Oncology Research Group 46
Next Page